Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. At 36 weeks, treatment with Taltz and Zepbound met the primary and all key secondary endpoints, delivering superior skin clearance and weight loss versus Taltz monotherapy.
In the study, 27.1% of participants receiving Taltz and Zepbound reached complete skin clearance or PASI 100 and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone. In a key secondary endpoint, Taltz plus Zepbound delivered a 40% relative increase over Taltz monotherapy in the proportion of patients who achieved PASI 100, demonstrating that treatment of obesity or overweight with Zepbound reduced the burden of psoriasis.
In pre-market trading on NYSE, Eli Lilly shares are up 0.25 percent to $1,039.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.